Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Clostridium difficile infection markets reached a value of US$ 9.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.9 Billion by 2034, exhibiting a growth rate (CAGR) of 4.7% during 2024-2034.
The Clostridium difficile infection market has been comprehensively analyzed in IMARC's new report titled "Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Clostridium difficile infection (CDI) refers to a bacterial infection caused by the pathogenic bacterium Clostridium difficile, commonly known as C. difficile. This bacterium can colonize the colon and disrupt the normal balance of gut flora, leading to a range of gastrointestinal symptoms. The indications of CDI can vary in severity and may include watery diarrhea, abdominal pain, fever, loss of appetite, and nausea. In severe cases, the ailment can progress to pseudomembranous colitis, a more severe inflammation of the colon, which can result in life-threatening complications. Diagnosing CDI typically involves several steps. The primary method is to test a stool sample for the presence of C. difficile toxins or the bacterium itself. A positive test result, along with clinical symptoms, is often sufficient to confirm the infection. Additionally, healthcare providers may perform a colonoscopy or sigmoidoscopy to visually inspect the colon for signs of inflammation or pseudomembranes.
The increasing utilization of broad-spectrum antibiotics, which can impair the balance of beneficial bacteria in the colon, thereby allowing C. difficile to overgrow and produce toxins that cause infection, is primarily driving the Clostridium difficile infection market. In addition to this, the inflating demand for effective medications, including vancomycin and fidaxomicin, as well as the emerging use of fecal microbiota transplantation (FMT) to restore a healthy gut microbiome, is also creating a positive outlook for the market. Moreover, the widespread adoption of infection control measures and stringent hygiene protocols in healthcare facilities, as they play a vital role in preventing CDI transmission, is further bolstering the market growth. Apart from this, the rising application of rapid diagnostic tests, such as enzyme immunoassays (EIAs) and nucleic acid amplification tests (NAATs), for early and accurate detection of the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatment modalities like monoclonal antibodies targeting bacterial toxins, which aid in neutralizing the harmful effects of the bacterium, is also augmenting the market growth. Furthermore, the ongoing research into novel vaccines against C. difficile, aimed at preventing CDI occurrence in high-risk populations is expected to drive the Clostridium difficile infection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Clostridium difficile infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Clostridium difficile infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Clostridium difficile infection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Clostridium difficile infection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Clostridium difficile infection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Clostridium difficile infection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Clostridium difficile infection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Clostridium difficile infection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Clostridium difficile infection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Clostridium difficile infection across the seven major markets?
What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by type across the seven major markets?
How many patients are diagnosed (2018-2034) with Clostridium difficile infection across the seven major markets?
What is the size of the Clostridium difficile infection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Clostridium difficile infection?
What will be the growth rate of patients across the seven major markets?
Clostridium Difficile Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Clostridium difficile infection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Clostridium difficile infection market?
What are the key regulatory events related to the Clostridium difficile infection market?
What is the structure of clinical trial landscape by status related to the Clostridium difficile infection market?
What is the structure of clinical trial landscape by phase related to the Clostridium difficile infection market?
What is the structure of clinical trial landscape by route of administration related to the Clostridium difficile infection market?
The Clostridium difficile infection market has been comprehensively analyzed in IMARC's new report titled "Clostridium Difficile Infection Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Clostridium difficile infection (CDI) refers to a bacterial infection caused by the pathogenic bacterium Clostridium difficile, commonly known as C. difficile. This bacterium can colonize the colon and disrupt the normal balance of gut flora, leading to a range of gastrointestinal symptoms. The indications of CDI can vary in severity and may include watery diarrhea, abdominal pain, fever, loss of appetite, and nausea. In severe cases, the ailment can progress to pseudomembranous colitis, a more severe inflammation of the colon, which can result in life-threatening complications. Diagnosing CDI typically involves several steps. The primary method is to test a stool sample for the presence of C. difficile toxins or the bacterium itself. A positive test result, along with clinical symptoms, is often sufficient to confirm the infection. Additionally, healthcare providers may perform a colonoscopy or sigmoidoscopy to visually inspect the colon for signs of inflammation or pseudomembranes.
The increasing utilization of broad-spectrum antibiotics, which can impair the balance of beneficial bacteria in the colon, thereby allowing C. difficile to overgrow and produce toxins that cause infection, is primarily driving the Clostridium difficile infection market. In addition to this, the inflating demand for effective medications, including vancomycin and fidaxomicin, as well as the emerging use of fecal microbiota transplantation (FMT) to restore a healthy gut microbiome, is also creating a positive outlook for the market. Moreover, the widespread adoption of infection control measures and stringent hygiene protocols in healthcare facilities, as they play a vital role in preventing CDI transmission, is further bolstering the market growth. Apart from this, the rising application of rapid diagnostic tests, such as enzyme immunoassays (EIAs) and nucleic acid amplification tests (NAATs), for early and accurate detection of the ailment is acting as another significant growth-inducing factor. Additionally, the emerging popularity of innovative treatment modalities like monoclonal antibodies targeting bacterial toxins, which aid in neutralizing the harmful effects of the bacterium, is also augmenting the market growth. Furthermore, the ongoing research into novel vaccines against C. difficile, aimed at preventing CDI occurrence in high-risk populations is expected to drive the Clostridium difficile infection market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Clostridium difficile infection market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Clostridium difficile infection and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Clostridium difficile infection market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Clostridium difficile infection market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Clostridium difficile infection market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Clostridium difficile infection marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Clostridium difficile infection market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Clostridium difficile infection market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Clostridium difficile infection market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Clostridium difficile infection across the seven major markets?
What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of Clostridium difficile infection by type across the seven major markets?
How many patients are diagnosed (2018-2034) with Clostridium difficile infection across the seven major markets?
What is the size of the Clostridium difficile infection patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Clostridium difficile infection?
What will be the growth rate of patients across the seven major markets?
Clostridium Difficile Infection: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Clostridium difficile infection drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Clostridium difficile infection market?
What are the key regulatory events related to the Clostridium difficile infection market?
What is the structure of clinical trial landscape by status related to the Clostridium difficile infection market?
What is the structure of clinical trial landscape by phase related to the Clostridium difficile infection market?
What is the structure of clinical trial landscape by route of administration related to the Clostridium difficile infection market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CLOSTRIDIUM DIFFICILE INFECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CLOSTRIDIUM DIFFICILE INFECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CLOSTRIDIUM DIFFICILE INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (??2018-2034)
7.2.4 Epidemiology by Gender (??2018-2034)
7.2.5 Epidemiology by Type (??2018-2034)
7.2.6 Diagnosed Cases (??2018-2034)
7.2.7 Patient Pool/Treated Cases (??2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (??2018-2034)
7.3.4 Epidemiology by Gender (??2018-2034)
7.3.5 Epidemiology by Type (??2018-2034)
7.3.6 Diagnosed Cases (??2018-2034)
7.3.7 Patient Pool/Treated Cases (??2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (??2018-2034)
7.4.4 Epidemiology by Gender (??2018-2034)
7.4.5 Epidemiology by Type (??2018-2034)
7.4.6 Diagnosed Cases (??2018-2034)
7.4.7 Patient Pool/Treated Cases (??2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (??2018-2034)
7.5.4 Epidemiology by Gender (??2018-2034)
7.5.5 Epidemiology by Type (??2018-2034)
7.5.6 Diagnosed Cases (??2018-2034)
7.5.7 Patient Pool/Treated Cases (??2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (??2018-2034)
7.6.4 Epidemiology by Gender (??2018-2034)
7.6.5 Epidemiology by Type (??2018-2034)
7.6.6 Diagnosed Cases (??2018-2034)
7.6.7 Patient Pool/Treated Cases (??2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (??2018-2034)
7.7.4 Epidemiology by Gender (??2018-2034)
7.7.5 Epidemiology by Type (??2018-2034)
7.7.6 Diagnosed Cases (??2018-2034)
7.7.7 Patient Pool/Treated Cases (??2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (??2018-2034)
7.8.4 Epidemiology by Gender (??2018-2034)
7.8.5 Epidemiology by Type (??2018-2034)
7.8.6 Diagnosed Cases (??2018-2034)
7.8.7 Patient Pool/Treated Cases (??2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (??2018-2034)
7.9.4 Epidemiology by Gender (??2018-2034)
7.9.5 Epidemiology by Type (??2018-2034)
7.9.6 Diagnosed Cases (??2018-2034)
7.9.7 Patient Pool/Treated Cases (??2018-2034)
8 CLOSTRIDIUM DIFFICILE INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CLOSTRIDIUM DIFFICILE INFECTION - UNMET NEEDS
10 CLOSTRIDIUM DIFFICILE INFECTION - KEY ENDPOINTS OF TREATMENT
11 CLOSTRIDIUM DIFFICILE INFECTION - MARKETED PRODUCTS
11.1 List of Clostridium Difficile Infection Marketed Drugs Across the Top 7 Markets
11.1.1 Zinplava (Bezlotoxumab) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rebyota (fecal microbiota, live - jslm) - Rebiotix
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vowst (fecal microbiota spores, live-brpk) - Seres Health
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Dificid (Fidaxomicin ) - Merck
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CLOSTRIDIUM DIFFICILE INFECTION - PIPELINE DRUGS
12.1 List of Clostridium Difficile Infection Pipeline Drugs Across the Top 7 Markets
12.1.1 VE303 - Vedanta Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 RBX7455 - Rebiotix
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CP101 - Finch Research and Development
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 MGB BP 3 - MGB Biopharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PF-06425090 - Pfizer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. CLOSTRIDIUM DIFFICILE INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CLOSTRIDIUM DIFFICILE INFECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CLOSTRIDIUM DIFFICILE INFECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Clostridium Difficile Infection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Clostridium Difficile Infection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Clostridium Difficile Infection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Clostridium Difficile Infection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Clostridium Difficile Infection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Clostridium Difficile Infection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Clostridium Difficile Infection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Clostridium Difficile Infection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Clostridium Difficile Infection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Clostridium Difficile Infection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Clostridium Difficile Infection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Clostridium Difficile Infection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Clostridium Difficile Infection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Clostridium Difficile Infection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Clostridium Difficile Infection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Clostridium Difficile Infection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Clostridium Difficile Infection - Access and Reimbursement Overview
16 CLOSTRIDIUM DIFFICILE INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CLOSTRIDIUM DIFFICILE INFECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CLOSTRIDIUM DIFFICILE INFECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CLOSTRIDIUM DIFFICILE INFECTION - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CLOSTRIDIUM DIFFICILE INFECTION - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CLOSTRIDIUM DIFFICILE INFECTION - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (??2018-2034)
7.2.4 Epidemiology by Gender (??2018-2034)
7.2.5 Epidemiology by Type (??2018-2034)
7.2.6 Diagnosed Cases (??2018-2034)
7.2.7 Patient Pool/Treated Cases (??2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (??2018-2034)
7.3.4 Epidemiology by Gender (??2018-2034)
7.3.5 Epidemiology by Type (??2018-2034)
7.3.6 Diagnosed Cases (??2018-2034)
7.3.7 Patient Pool/Treated Cases (??2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (??2018-2034)
7.4.4 Epidemiology by Gender (??2018-2034)
7.4.5 Epidemiology by Type (??2018-2034)
7.4.6 Diagnosed Cases (??2018-2034)
7.4.7 Patient Pool/Treated Cases (??2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (??2018-2034)
7.5.4 Epidemiology by Gender (??2018-2034)
7.5.5 Epidemiology by Type (??2018-2034)
7.5.6 Diagnosed Cases (??2018-2034)
7.5.7 Patient Pool/Treated Cases (??2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (??2018-2034)
7.6.4 Epidemiology by Gender (??2018-2034)
7.6.5 Epidemiology by Type (??2018-2034)
7.6.6 Diagnosed Cases (??2018-2034)
7.6.7 Patient Pool/Treated Cases (??2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (??2018-2034)
7.7.4 Epidemiology by Gender (??2018-2034)
7.7.5 Epidemiology by Type (??2018-2034)
7.7.6 Diagnosed Cases (??2018-2034)
7.7.7 Patient Pool/Treated Cases (??2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (??2018-2034)
7.8.4 Epidemiology by Gender (??2018-2034)
7.8.5 Epidemiology by Type (??2018-2034)
7.8.6 Diagnosed Cases (??2018-2034)
7.8.7 Patient Pool/Treated Cases (??2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (??2018-2034)
7.9.4 Epidemiology by Gender (??2018-2034)
7.9.5 Epidemiology by Type (??2018-2034)
7.9.6 Diagnosed Cases (??2018-2034)
7.9.7 Patient Pool/Treated Cases (??2018-2034)
8 CLOSTRIDIUM DIFFICILE INFECTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CLOSTRIDIUM DIFFICILE INFECTION - UNMET NEEDS
10 CLOSTRIDIUM DIFFICILE INFECTION - KEY ENDPOINTS OF TREATMENT
11 CLOSTRIDIUM DIFFICILE INFECTION - MARKETED PRODUCTS
11.1 List of Clostridium Difficile Infection Marketed Drugs Across the Top 7 Markets
11.1.1 Zinplava (Bezlotoxumab) - Merck & Co
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Rebyota (fecal microbiota, live - jslm) - Rebiotix
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vowst (fecal microbiota spores, live-brpk) - Seres Health
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Dificid (Fidaxomicin ) - Merck
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CLOSTRIDIUM DIFFICILE INFECTION - PIPELINE DRUGS
12.1 List of Clostridium Difficile Infection Pipeline Drugs Across the Top 7 Markets
12.1.1 VE303 - Vedanta Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 RBX7455 - Rebiotix
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CP101 - Finch Research and Development
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 MGB BP 3 - MGB Biopharma
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 PF-06425090 - Pfizer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report
13. CLOSTRIDIUM DIFFICILE INFECTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CLOSTRIDIUM DIFFICILE INFECTION – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CLOSTRIDIUM DIFFICILE INFECTION - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Clostridium Difficile Infection - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Clostridium Difficile Infection - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Clostridium Difficile Infection - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Clostridium Difficile Infection - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Clostridium Difficile Infection - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Clostridium Difficile Infection - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Clostridium Difficile Infection - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Clostridium Difficile Infection - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Clostridium Difficile Infection - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Clostridium Difficile Infection - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Clostridium Difficile Infection - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Clostridium Difficile Infection - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Clostridium Difficile Infection - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Clostridium Difficile Infection - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Clostridium Difficile Infection - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Clostridium Difficile Infection - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Clostridium Difficile Infection - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Clostridium Difficile Infection - Access and Reimbursement Overview
16 CLOSTRIDIUM DIFFICILE INFECTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CLOSTRIDIUM DIFFICILE INFECTION MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CLOSTRIDIUM DIFFICILE INFECTION MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
